Murky documentation of meetings between Biogen and the FDA, plus an “unjustifiably high price” for a drug that lacked clinical data, are at fault for the Adulelm controversy, two House committees said Dec. 29 in a report.
Read the full post on Becker's Hospital Review - Healthcare News
